Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers

NCT02222961 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-08-22

No results posted yet for this study

Summary
Conditions
Interventions
Sponsors
Investigators
Design
Eligibility
Timeline
Countries
Locations
Related
Entities

Summary

The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIIR 561 after continuous intravenous administration of increasing doses in healthy young volunteers

Conditions

Healthy

Interventions

DRUG: BIIR 561 CL
DRUG: Placebo

Sponsors & Collaborators

Boehringer Ingelheim
lead INDUSTRY

Study Design

Allocation: RANDOMIZED
Purpose: TREATMENT
Masking: SINGLE
Model: PARALLEL

Eligibility

Min Age: 21 Years
Max Age: 50 Years
Sex: MALE
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 1999-11-30
Primary Completion: 2000-06-30

More Related Trials

Entities

Drugs

Placebo

Companies

Boehringer Ingelheim

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Related Clinical Trials

Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL

Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

More Related Trials

Entities